Wire
Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer
Telomir Pharmaceuticals (TELO) said Thursday the US Food and Drug Administration has approved its investigational new drug application for its lead candidate Telomir-Zn to treat people with advanced or metastatic triple-negative breast cancer.The clearance will allow the company to advance Telomir-Zn into clinical evaluation, Telomir said, adding it plans to start the first-in-human phase 1/2 trial in H1.Telomir shares were down over 2% in Thursday morning trading.Price: $1.43, Change: $-0.02, Percent Change: -1.38%
$TELO
